Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children

Abstract

Pediatric patients with psoriasis, in order to maintain long-term remission, as a rule, need long-term therapy with genetically engineered biological drugs (GEBDs), which they continue after reaching adulthood. However, over time, there is a decrease in the effectiveness of biological therapy up to the complete loss of the therapeutic response, resulting in the need to change the biological therapy. In this regard, the study of the survival rate of biological therapy and the conditions and factors influencing it is becoming an urgent topic for research, which will make it possible to implement a personalized approach to prescribing GEBA and improve the effectiveness of the treatment. This article provides information on the main aspects of the survival of biological therapy in children with psoriasis, as well as the results of research on this issue.